Pramlintide (Symlin)

FDA-approved context Weight Loss & Metabolism 2 sources

Pramlintide is a synthetic analog of human amylin, a hormone co-secreted with insulin by pancreatic beta cells. It is FDA-approved as an adjunct treatment for type 1 and type 2 diabetes to help control postprandial blood glucose levels, delay gastric emptying, and promote satiety.

01Dosing reference

Amount

15-120 mcg per dose (depending on diabetes type)

Frequency

Administered prior to major meals

Cycle

Continuous daily use as prescribed

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Amylin Receptor Agonism

Binds to and activates amylin receptors located primarily in the hindbrain.

Gastric Slowing and Glucagon Suppression

Slows the rate of gastric emptying and suppresses inappropriate postprandial glucagon secretion.

Glycemic Control and Satiety

Reduces post-meal blood sugar spikes and promotes a feeling of fullness, which can lead to reduced caloric intake.

03Human evidence

Significant reduction in HbA1c and postprandial glucose excursions in patients with type 1 and type 2 diabetes.

Demonstrated in multiple large-scale randomized controlled trials that led to its FDA approval.

Modest but sustained weight loss observed in diabetic and obese patients.

Clinical trials evaluating its effect on body weight independent of its glycemic control benefits.

04Preclinical evidence

Demonstrated reduction in food intake and body weight in rodent models of obesity.

Animal studies evaluating the role of amylin agonism on energy balance and metabolic regulation.

Showed synergistic effects on weight loss when combined with GLP-1 receptor agonists or leptin.

Preclinical models exploring combination therapies for enhanced obesity treatment.

05What is known vs. unknown

Reasonably established

Synthetic analog of the naturally occurring hormone amylin.
FDA-approved for use with mealtime insulin in type 1 and type 2 diabetes.
Slows gastric emptying and suppresses inappropriate glucagon secretion.
Promotes satiety, often resulting in modest weight loss.

Unknowns & limits

Long-term cardiovascular outcomes compared to newer GLP-1 receptor agonists are less established.
The exact mechanisms of synergy with other weight-loss peptides (like leptin) in humans require further large-scale trials.

06Safety & regulatory context

Regulatory statusPramlintide is FDA-approved under the brand name Symlin for patients with type 1 and type 2 diabetes who use mealtime insulin. It carries a Black Box Warning for severe insulin-induced hypoglycemia, particularly in type 1 diabetes. Common side effects include nausea, vomiting, anorexia, and headache. It is contraindicated in patients with gastroparesis or hypoglycemia unawareness.

07Compared with Semaglutide

Pramlintide (Symlin) vs. Semaglutide

Key difference

Pramlintide is an amylin analog that must be injected at mealtime and is primarily used with insulin, whereas Semaglutide is a GLP-1 receptor agonist often used once weekly with more profound weight loss effects.

When researchers discuss each

Pramlintide is discussed when addressing postprandial glucose spikes and amylin deficiency in insulin-dependent diabetes, while Semaglutide is discussed for broad glycemic control, significant weight loss, and cardiovascular risk reduction.

08Glossary

Amylin

A peptide hormone co-secreted with insulin from the pancreas that helps regulate glucose metabolism.

Gastric emptying

The process by which food leaves the stomach and enters the small intestine.

Postprandial

Occurring after a meal, often used in reference to blood sugar levels.

09Knowledge check

Q1What is the primary mechanism of action of Pramlintide?

Q2Which of the following is a major safety warning associated with Pramlintide?

Q3Which statement best reflects a documented limitation of the evidence base for pramlintide in the dossier?

Q4In comparative research context described in the dossier, pramlintide is most likely to be discussed for which of the following roles?

Q5Which of the following is listed in the dossier as a contraindication for pramlintide?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.